Mason Street Advisors LLC raised its stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 1.6% during the first quarter, Holdings Channel reports. The firm owned 10,509 shares of the biopharmaceutical company’s stock after buying an additional 168 shares during the period. Mason Street Advisors LLC’s holdings in Regeneron Pharmaceuticals were worth $4,072,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also bought and sold shares of the company. Korea Investment CORP raised its position in Regeneron Pharmaceuticals by 223.9% in the first quarter. Korea Investment CORP now owns 298 shares of the biopharmaceutical company’s stock valued at $115,000 after buying an additional 206 shares during the period. Alpha Windward LLC raised its position in Regeneron Pharmaceuticals by 4.4% in the first quarter. Alpha Windward LLC now owns 383 shares of the biopharmaceutical company’s stock valued at $148,000 after buying an additional 16 shares during the period. Live Your Vision LLC acquired a new position in Regeneron Pharmaceuticals during the third quarter valued at about $157,000. Blenheim Capital Management BV acquired a new position in Regeneron Pharmaceuticals during the fourth quarter valued at about $160,000. Finally, March Altus Capital Management LP acquired a new position in Regeneron Pharmaceuticals during the third quarter valued at about $201,000. 68.83% of the stock is owned by hedge funds and other institutional investors.
Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) traded down 0.05% on Friday, hitting $455.45. The company had a trading volume of 380,289 shares. The company has a market capitalization of $48.08 billion, a price-to-earnings ratio of 55.13 and a beta of 1.44. The stock’s 50-day moving average is $408.39 and its 200 day moving average is $385.04. Regeneron Pharmaceuticals Inc has a 52 week low of $325.35 and a 52 week high of $464.40. Regeneron Pharmaceuticals also saw some unusual options trading on Tuesday. Investors acquired 389 put options on the stock. This represents an increase of 232% compared to the typical volume of 117 put options.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings results on Thursday, May 4th. The biopharmaceutical company reported $2.92 earnings per share for the quarter, beating the consensus estimate of $2.50 by $0.42. The company had revenue of $1.32 billion during the quarter, compared to analysts’ expectations of $1.30 billion. Regeneron Pharmaceuticals had a return on equity of 22.51% and a net margin of 18.10%. Regeneron Pharmaceuticals’s quarterly revenue was up 9.8% on a year-over-year basis. During the same period last year, the business earned $2.57 earnings per share. Equities analysts expect that Regeneron Pharmaceuticals Inc will post $12.68 EPS for the current year.
REGN has been the topic of several research analyst reports. Oppenheimer Holdings Inc. initiated coverage on shares of Regeneron Pharmaceuticals in a research note on Thursday, March 16th. They set a “hold” rating on the stock. Vetr cut shares of Regeneron Pharmaceuticals from a “sell” rating to a “strong sell” rating and set a $368.84 price objective on the stock. in a research note on Monday, May 15th. Leerink Swann set a $448.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “buy” rating in a research note on Tuesday, March 28th. Canaccord Genuity set a $450.00 price objective on shares of Regeneron Pharmaceuticals and gave the stock a “hold” rating in a research note on Friday, February 3rd. Finally, BTIG Research reaffirmed a “buy” rating and set a $460.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Wednesday, March 29th. One investment analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and twelve have issued a buy rating to the company’s stock. The stock has an average rating of “Hold” and an average price target of $432.21.
In related news, Director Michael S. Brown sold 3,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, May 12th. The stock was sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the completion of the transaction, the director now directly owns 3,000 shares in the company, valued at $1,350,000. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Michael S. Brown sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, March 29th. The shares were sold at an average price of $400.00, for a total value of $400,000.00. Following the transaction, the director now owns 1,000 shares of the company’s stock, valued at $400,000. The disclosure for this sale can be found here. 10.40% of the stock is currently owned by company insiders.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
This story was originally published by sleekmoney (https://sleekmoney.com) and is the sole property of sleekmoney. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://sleekmoney.com/regeneron-pharmaceuticals-inc-regn-stake-boosted-by-mason-street-advisors-llc/1856740.html
Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.